SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000905718-17-000646
Filing Date
2017-07-05
Accepted
2017-07-05 16:39:19
Documents
2
Period of Report
2017-07-01

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT martin_fm3jun302017.html 3  
1 OWNERSHIP DOCUMENT martin_fm3jun302017.xml 3 10216
2 POWER OF ATTORNEY martin_poa.htm EX-99 4926
  Complete submission text file 0000905718-17-000646.txt   16768
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Issuer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON NJ 08827
Business Address
Martin Samuel Bates (Reporting) CIK: 0001709024 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-15006 | Film No.: 17948643